文献速递血栓与止血

血友病A基因治疗后FVIII显色活性与抗原水平的相关性

Correlation between Factor VIII chromogenic activity and antigen levels in patients treated with adeno-associated virus 5-mediated gene therapy for hemophilia A.
PubMed 文献 · J Thromb Haemost · 2026-04-28

本研究纳入4例接受valoctocogene roxaparvovec(6×10^13 vg/kg)的严重血友病A成人患者,采集182份血浆样本,比较OSA与CA测定的FVIII活性及转基因FVIII抗原水平。结果显示OSA测定的FVIII活性持续为CA的1.6–2倍,且转基因FVIII抗原与CA活性正相关,支持CA作为基因治疗后监测FVIII表达的首选方法。

要点

  • OSA测定的FVIII活性持续为CA的1.6–2倍。
  • 转基因FVIII抗原水平与CA测定的FVIII活性正相关。
  • CA可作为基因治疗后监测FVIII表达的首选方法。

核心结论

  • FVIII抗原水平与CA结果高度一致,支持CA作为监测基因治疗后FVIII表达的首选方法。

研究设计与样本

  • 4例严重血友病A成人患者接受单次valoctocogene roxaparvovec输注(6×10^13 vg/kg)。
  • 共采集182份血浆样本,多时间点测定FVIII活性(OSA和CA)及转基因FVIII抗原。

主要发现

  • 患者中位随访时间为61周(IQR 52.5–115.7)。
  • OSA测定的FVIII活性持续为CA的1.6–2倍,与既往临床试验观察一致。
  • 转基因FVIII抗原水平与CA测定的FVIII活性正相关,提示转基因有效转录和翻译。

临床怎么用

  • 基因治疗后监测FVIII表达时,CA较OSA更准确反映转基因产物水平。
  • 建议采用多方法策略全面评估转基因表达和临床管理。

局限性

  • 样本量仅4例,随访时间有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Gene therapy for hemophilia A with valoctocogene roxaparvovec, an adeno-associated virus (AAV) vector encoding B-domain-deleted factor (F)VIII, enables sustained endogenous FVIII expression and long-term bleed protection. FVIII activity is commonly measured using a one-stage clotting assay (OSA) or a chromogenic assay (CA), which yield discrepant results. Data on FVIII transgene expression, assessed by antigen measurements after gene therapy in humans, remain limited. OBJECTIVE: To evaluate the correlation between FVIII activity assessed by OSA and CA and FVIII antigen levels after valoctocogene roxaparvovec administration. METHODS: Four adult patients with severe hemophilia A received a single infusion of valoctocogene roxaparvovec (6 × 1013 vg/kg). FVIII activity was measured by OSA and CA methods; FVIII antigen was quantified using an enzyme-linked immunosorbent assay optimized for B-domain-deleted FVIII. A total of 182 plasma samples were collected at multiple time points post-AAV5 FVIII dosing. RESULTS: The median follow-up time for patients was 61 weeks (IQR, 52.5-115.7). The OSA consistently showed FVIII activity 1.6- to 2-fold higher than the CA, consistent with observations from previous clinical trials. Transgenic FVIII antigen levels positively correlated with FVIII activity measured by the CA, indicating effective transcription and translation of the FVIII transgene. CONCLUSION: FVIII antigen levels showed strong concordance with CA results following AAV-mediated gene therapy. These findings support the CA as the preferred method for monitoring therapeutic FVIII expression in patients treated with gene therapy for hemophilia A. Multiassay strategies remain essential for comprehensive assessment of transgene expression and clinical management after gene therapy.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Peyvandi F, Garagiola I, Novembrino C, et al. Correlation between Factor VIII chromogenic activity and antigen levels in patients treated with adeno-associated virus 5-mediated gene therapy for hemophilia A. J Thromb Haemost. 2026. PMID: 42061679. doi:10.1016/j.jtha.2026.04.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。